Status:
UNKNOWN
Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19
Lead Sponsor:
Tanta University
Conditions:
COVID-19
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
In December 2019, a new infectious respiratory disease emerged in Wuhan, Hubei province, China. An initial cluster of infections was linked to Huanan seafood market, potentially due to animal contact....
Detailed Description
Selected Drugs Hydroxychloroquine (an analog of chloroquine) has been demonstrated to have an anti-SARS-CoV activity in vitro. Hydroxychloroquine clinical safety profile is better than that of chloro...
Eligibility Criteria
Inclusion
- Confirmed cases of COVID-19 (Positive RT-PCR)
- Newly diagnosed symptomatic patients.
- Adults (18-65 Years old)
- Both sexes
Exclusion
- Patients with abnormal liver function (ALT, AST), chronic kidney disease or dialysis (CrCl\< 30 ml/min)
- Pregnant women or women who are breastfeeding
- Immunocompromised patients taking medication upon screening
- Subjects with comorbid condition like hypertension, cardiovascular disease, diabetes mellites, asthma, COPD, malignancy
- Patients having allergy to Hydroxychloroquine and/or Nitazoxanide
- Patients with contraindication towards the study medication including retinopathy, G6PD deficiency and QT prolongation.
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04361318
Start Date
May 1 2020
End Date
December 1 2020
Last Update
April 24 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.